RAPPRapport Therapeutics, Inc.
Is it safe?
Caution warranted: heavy debt (CCC) and big price swings.
Insiders were net sellers (-$7.3M, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -76% · now 41% below its 52-week high.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RAPP take a bad year?
The deepest fall in RAPP's price history on file is −76%; it is 42% below its high today.
Worst drawdown on file · −42% today
- Cash runway
- 4.5 years
Cash runway · burning $24M a quarter at the current rate
- Annualised volatility
- 120%
Annualised volatility · three times the market's own swing
Details›
- Cash and short-term investments
- $436M
- EBITDA, trailing twelve months
- −$153M
- Operating profit, trailing twelve months
- −$154M
- Annualised volatilitytwo years of daily moves
- 120%
- Worst drawdown on file
- −76%
- Below its 52-week high
- 42%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry